SCHEMBL613592

SCHEMBL613592

CCNc1cc(Br)sc1C(=O)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 2/20 0.40
ATM Q13315 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PPARG P37231 1/20 0.39
NCOA1 Q15788 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
RAF1 P04049 4/20 0.39
KMT2A Q03164 4/20 0.38
MAPT P10636 3/20 0.38
TSHR P16473 1/20 0.38
MAPK14 Q16539 3/20 0.38
LMNA P02545 2/20 0.38
GSK3B P49841 1/20 0.38
CASP3 P42574 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SENP8 Q96LD8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612156 0.83 MAPT (0.42) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL613309 0.82 IKBKB (0.40) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL613554 0.82 PPARG (0.36) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL23452086 0.80 CA1 (0.49) KDM4EALDH1A1HPGDL3MBTL1NPSR1
SCHEMBL21411362 0.79 ALDH1A1 (0.58) KDM4EALDH1A1HPGDATML3MBTL1
SCHEMBL1458749 0.79 RAF1 (0.46) ALDH1A1L3MBTL1RAF1KMT2AMAPT
SCHEMBL29122566 0.78 HSD17B10 (0.42) KDM4EALDH1A1HPGDHSD17B10ATM
SCHEMBL612035 0.78 POLB (0.49) KDM4EALDH1A1L3MBTL1KMT2AMAPT
SCHEMBL1406076 0.77 MAPT (0.47) KDM4EALDH1A1HPGDATMPPARG
SCHEMBL669321 0.77 RAF1 (0.39) KDM4EALDH1A1HPGDHSD17B10ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK KDM4E 1319/4885ALDH1A1 1927/4885HPGD 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.